Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2012 1
2013 6
2014 46
2015 162
2016 243
2017 274
2018 282
2019 166
2020 133
2021 119
2022 80
2023 44
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

1,360 results

Results by year

Filters applied: . Clear all
Page 1
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.
Scott LJ. Scott LJ. Drugs. 2018 Feb;78(2):245-256. doi: 10.1007/s40265-018-0864-z. Drugs. 2018. PMID: 29380288 Review.

Oral once-daily, fixed-dose, ledipasvir/sofosbuvir (Harvoni()) [ ribavirin] is approved in several countries for the treatment of chronic hepatitis C (CHC) in adults and adolescents aged 12 to < 18 years, with direct-acting antiviral (DAA) regimens resulting in a paradi

…
Oral once-daily, fixed-dose, ledipasvir/sofosbuvir (Harvoni()) [ ribavirin] is approved in several countries for the treatment of chr …
Ledipasvir with sofosbuvir.
[No authors listed] [No authors listed] Aust Prescr. 2015 Dec;38(6):219-21. doi: 10.18773/austprescr.2015.078. Epub 2015 Oct 14. Aust Prescr. 2015. PMID: 26843718 Free PMC article. Review. No abstract available.
Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.
Keating GM. Keating GM. Drugs. 2015 Apr;75(6):675-85. doi: 10.1007/s40265-015-0381-2. Drugs. 2015. PMID: 25837989 Review.
The single-tablet regimen of the hepatitis C virus (HCV) NS5A inhibitor ledipasvir and the HCV NS5B polymerase inhibitor sofosbuvir (ledipasvir/sofosbuvir; Harvoni()) was recently approved in the US and the EU. ...Oral ledipasvir/sofosbuvir was generally well …
The single-tablet regimen of the hepatitis C virus (HCV) NS5A inhibitor ledipasvir and the HCV NS5B polymerase inhibitor sofosbuvir ( …
Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
Smith MA, Chan J, Mohammad RA. Smith MA, et al. Ann Pharmacother. 2015 Mar;49(3):343-50. doi: 10.1177/1060028014563952. Epub 2014 Dec 16. Ann Pharmacother. 2015. PMID: 25515863 Review.
OBJECTIVES: To review the pharmacology, efficacy, and safety of ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus (HCV). ...The most common adverse drug events (ADEs) associated with ledipasvir-sofosbuvir include headache, fatigue, insomnia, nause …
OBJECTIVES: To review the pharmacology, efficacy, and safety of ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus …
Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir.
German P, Mathias A, Brainard DM, Kearney BP. German P, et al. Clin Pharmacokinet. 2018 Nov;57(11):1369-1383. doi: 10.1007/s40262-018-0654-5. Clin Pharmacokinet. 2018. PMID: 29644537 Review.
Ledipasvir/sofosbuvir (Harvoni()), a fixed-dose combination tablet of an NS5A inhibitor ledipasvir and an NS5B polymerase inhibitor sofosbuvir, is approved for the treatment of chronic hepatitis C virus infection. ...This review summarizes a number of drug interacti …
Ledipasvir/sofosbuvir (Harvoni()), a fixed-dose combination tablet of an NS5A inhibitor ledipasvir and an NS5B polymerase inhi …
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
Rosenthal ES, Kottilil S, Polis MA. Rosenthal ES, et al. Expert Opin Pharmacother. 2016;17(5):743-9. doi: 10.1517/14656566.2016.1157580. Epub 2016 Mar 16. Expert Opin Pharmacother. 2016. PMID: 26898158 Free PMC article. Review.
AREAS COVERED: In this paper, we review the evidence supporting the use of ledipasvir and sofosbuvir (LDV/SOF) for the treatment of HCV in patients with HIV co-infection. ...
AREAS COVERED: In this paper, we review the evidence supporting the use of ledipasvir and sofosbuvir (LDV/SOF) for the treatment of H …
Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection.
Nehra V, Tan EM, Rizza SA, Temesgen Z. Nehra V, et al. Drugs Today (Barc). 2016 Feb;52(2):111-7. doi: 10.1358/dot.2016.52.2.2449840. Drugs Today (Barc). 2016. PMID: 27092340 Review.
Recently a single tablet, fixed-dose combination of sofosbuvir, an RNA-directed RNA polymerase (NS5B) inhibitor, and ledipasvir, a nonstructural protein 5A (NS5A) inhibitor, has been approved for treatment of chronic HCV infection. Two studies using the fixed-dose combinat …
Recently a single tablet, fixed-dose combination of sofosbuvir, an RNA-directed RNA polymerase (NS5B) inhibitor, and ledipasvir, a no …
An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection.
Balatow P, Sandlin A, Cory TJ. Balatow P, et al. Expert Opin Pharmacother. 2021 Oct;22(14):1839-1846. doi: 10.1080/14656566.2021.1943359. Epub 2021 Jul 1. Expert Opin Pharmacother. 2021. PMID: 34157923 Free PMC article. Review.
These drugs have shown efficacy over 90% throughout the class as well as a better safety profile than the previous recommended pharmacotherapy. Dual-therapy DAAs emerged with FDA approval of Ledipasvir/Sofosbuvir (LDV/SOF) in 2014.Areas Covered: LDV/SOF is a dual-therapy o …
These drugs have shown efficacy over 90% throughout the class as well as a better safety profile than the previous recommended pharmacothera …
Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection.
Gentile I, Buonomo AR, Borgia F, Castaldo G, Borgia G. Gentile I, et al. Expert Opin Investig Drugs. 2014 Apr;23(4):561-71. doi: 10.1517/13543784.2014.892581. Epub 2014 Mar 4. Expert Opin Investig Drugs. 2014. PMID: 24593285 Review.
AREAS COVERED: This review focuses on the pharmacokinetics, pharmacodynamics and tolerability of ledipasvir , an inhibitor of HCV nonstructural 5A protein. The authors also highlight the drug's safety and resistance profile. EXPERT OPINION: The pharmacokinetic profile and …
AREAS COVERED: This review focuses on the pharmacokinetics, pharmacodynamics and tolerability of ledipasvir , an inhibitor of HCV non …
Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection.
Jensen CM, Holle LM. Jensen CM, et al. Pharmacotherapy. 2016 May;36(5):562-74. doi: 10.1002/phar.1748. Epub 2016 May 12. Pharmacotherapy. 2016. PMID: 27027412 Review.
In recent years, however, treatment options for chronic HCV infection have rapidly changed to an all-oral regimen. Ledipasvir-sofosbuvir is an oral fixed-dose (ledipasvir 90 mg-sofosbuvir 400 mg) combination of two direct-acting antiviral drugs. Four phase 3 clinica …
In recent years, however, treatment options for chronic HCV infection have rapidly changed to an all-oral regimen. Ledipasvir-sofosbu …
1,360 results

Searches related to "ledipasvir"